rivotril clonazepam 0.5mg tablet blister pack
pharmaco australia ltd - clonazepam, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: iron oxide red; magnesium stearate; pregelatinised potato starch; purified talc; maize starch; iron oxide yellow; lactose monohydrate - tablets: most types epilepsy in infants and children, especially absences (petit mal), myoclonic seizures and tonic-clonic fits, whether due to primary generalised epilepsy, or to secondary generalisation of partial epilepsy. in adults all varieties of generalised epilepsy (including myoclonic, akinetic, tonic and tonic-clonic seizures), and in partial epilepsy (including psychomotor seizures).
carbaglu carglumic acid 200 mg dispersible tablets tube
recordati rare diseases australia pty ltd - carglumic acid, quantity: 200 mg - tablet, dispersible - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; sodium lauryl sulfate; croscarmellose sodium; hypromellose; sodium stearylfumarate - carbaglu is indicated in treatment of,? hyperammonaemia due to n-acetylglutamate synthase primary deficiency,? hyperammonaemia due to organic acidaemias such as:,-hyperammonaemia due to isovaleric acidaemia -hyperammonaemia due to methylmalonic acidaemia -hyperammonaemia due to propionic acidaemia
amisulpride sandoz pharma amisulpride 100 mg uncoated tablet blister pack
southern cross pharma pty ltd - amisulpride, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a; hypromellose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
amisulpride sandoz pharma amisulpride 200 mg uncoated tablet blister pack
southern cross pharma pty ltd - amisulpride, quantity: 200 mg - tablet, uncoated - excipient ingredients: hypromellose; lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
amisulpride sandoz pharma amisulpride 400 mg uncoated tablet blister pack
southern cross pharma pty ltd - amisulpride, quantity: 400 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; hypromellose; microcrystalline cellulose; magnesium stearate; lactose monohydrate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
sulprix amisulpride 200 mg tablets blister pack
alphapharm pty ltd - amisulpride, quantity: 200 mg - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; hypromellose; lactose monohydrate; sodium starch glycollate type a - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
sulprix amisulpride 100 mg tablets blister pack
alphapharm pty ltd - amisulpride, quantity: 100 mg - tablet - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; hypromellose; sodium starch glycollate type a - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
sulprix amisulpride 400 mg tablets blister pack
alphapharm pty ltd - amisulpride, quantity: 400 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hypromellose; sodium starch glycollate type a; magnesium stearate; lactose monohydrate; titanium dioxide; macrogol 400 - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
amipride 400 amisulpride 400 mg tablet blister pack
arrotex pharmaceuticals pty ltd - amisulpride, quantity: 400 mg - tablet, film coated - excipient ingredients: titanium dioxide; purified talc; lactose monohydrate; methylcellulose; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; macrogol 600; basic butylated methacrylate copolymer - treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent.
amisulpride 200 winthrop amisulpride 200 mg tablet blister pack
sanofi-aventis australia pty ltd - amisulpride, quantity: 200 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; microcrystalline cellulose; magnesium stearate; hypromellose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.